SUBSCRIBERS

Gilead wins reversal of US$2.54b hepatitis C drug patent verdict

Published Sun, Feb 18, 2018 · 09:50 PM

Boston

A US federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record US$2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

The verdict had been the largest ever in a US patent case but US District Judge Leonard Stark in W…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

Companies & Markets

Gilead wins reversal of US$2.54b hepatitis C drug patent verdict

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece

P&G raises annual core profit forecast on resilient demand, price hikes

Cordlife calls for trading halt after shares sink to all-time low, pending announcement

Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom

Swiss watch exports plunge as China and Hong Kong demand dries up

Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT